Extending the Potential of the Treatment of Multiple Sclerosis with a New Agent for Oral Use - Teriflunomide (Aubagio)

摘要

Teriflunomide is a new oral agent for the treatment of the recurring-remitting form of multiple sclerosis, its efficacy being demonstrated as a reduction in the frequency of exacerbations. Data obtained by MRI scanning have also confirmed its clinical efficacy. Single daily doses of teriflunomide are safe and well tolerated, with the development of mild and transient side effects. Nonetheless, a risk management plan should be put in place with the aims of minimizing and monitoring adverse effects during treatment.